Shots:

• The approval is based on clinical study results assessing Trogarzo (ibalizumab- IV) in 40 patients with MDR-HIV
• The study resulted in depletion of HIV-RNA level in blood in 43% patients after 24 weeks when given with other antiretroviral drugs
• Trogarvo (ibalizumab- IV) is an antiretroviral drug used in treatment of MDR-HIV and received FDA’s FT- PR- OD and breakthrough therapy in 2003- 2017- 2014 & 2015 respectively.

Ref: FDA | Image: Bioworld